Illumina plans to divest Grail, which it bought over the objection of regulators...
Structure Therapeutics' GLP-1 pill demonstrated a 1% lowering of blood glucose a...
The current state of patient advocacy needs reform so that the best, safest drug...
Amy Abernethy, the president of product development and chief medical officer at...
American taxpayers footed the bill for about 41% of the nearly $4.5 trillion in ...
Understand how science, health policy, and medicine shape the world everyday. Si...
Want to stay on top of the science and politics driving biotech today? Sign up t...
Highly effective anti-obesity drugs like Wegovy are increasingly being paired wi...
Overly broad Census categories force tens of millions of Americans to select “so...
A special European policy allows researchers at hospitals to make their own adva...
FTC, DOJ, and HHS are adding new officials to investigate price-gouging in healt...
It's time for @adamfeuerstein's list of Worst Biophama CEOs of the year.
CymaBay Therapeutics has filed a new drug application (NDA) with the FDA seeking...
The EMA CHMP recommended granting approval for Takeda’s Hyqvia for chronic infla...
The US FDA approved Astellas Pharma-Pfizer’s Padcev plus Merck’s (MSD) Keytruda ...
The latest $389m pledge follows an initial investment of $300m in 2017 that was ...
